RARE
Ultragenyx
NASDAQ: RARE · HEALTHCARE · BIOTECHNOLOGY
$24.18
-1.43% today
Updated 2026-04-29
Market cap
$2.38B
P/E ratio
—
P/S ratio
3.53x
EPS (TTM)
$-5.83
Dividend yield
—
52W range
$18 – $42
Volume
2.0M
Ultragenyx (RARE) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-85.40%
Operating margin
-54.60%
ROE
-608.00%
ROA
-22.00%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | — | $-6.85M | — | — | — |
| 2012 | — | $-16.33M | — | — | — |
| 2013 | — | $-35.07M | — | — | — |
| 2014 | $0.00 | $-59.80M | — | — | — |
| 2015 | $0.00 | $-145.62M | — | — | — |
| 2016 | $133000.00 | $-245.87M | 100.00% | -186,471.43% | -184,867.67% |
| 2017 | $2.61M | $-302.14M | 99.96% | -12,593.49% | -11,567.34% |
| 2018 | $51.49M | $-197.61M | 97.77% | -721.18% | -383.75% |
| 2019 | $103.71M | $-402.73M | 91.31% | -408.98% | -388.31% |
| 2020 | $271.03M | $-186.57M | 97.74% | -121.80% | -68.84% |
| 2021 | $351.41M | $-454.02M | 95.44% | -108.63% | -129.20% |
| 2022 | $363.33M | $-707.42M | 92.21% | -178.60% | -194.71% |
| 2023 | $434.25M | $-606.64M | 89.59% | -131.08% | -139.70% |
| 2024 | $560.23M | $-569.18M | 86.30% | -95.67% | -101.60% |
| 2025 | $673.00M | $-575.00M | 83.80% | -79.49% | -85.44% |